https://www.selleckchem.com/products/loxo-195.html
04; 95% confidence interval [CI] 0.99-1.09; P = 0.14), as were likelihoods of other secondary outcomes. In the subgroup analysis, baloxavir use was associated with higher medical resource use than oseltamivir (aOR 1.21; 95% CI 1.13-1.31; P 0.001) and lower resource use than zanamivir (aOR 0.93; 95% CI 0.86-1.00; P = 0.04. Based on a single-year experience in Japan, prescribing baloxavir rather than NAIs did not increase medical resource utilization within 9 days of treatment, except in one exploratory comparison with oseltamivir